These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 22288665)
1. The six gaps in the search of neuroprotection for Parkinson's disease. Espay AJ; Fasano A; Morgante F Expert Rev Neurother; 2012 Feb; 12(2):111-3. PubMed ID: 22288665 [No Abstract] [Full Text] [Related]
2. Designing neuroprotection trials in Parkinson's disease. Kieburtz K Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102 [TBL] [Abstract][Full Text] [Related]
3. Neuroprotection for Parkinson's disease: prospects and promises. Olanow CW; Schapira AH; Agid Y Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093 [No Abstract] [Full Text] [Related]
7. Clinical aspects of neuroprotection in Parkinson's disease. Przuntek H J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398 [TBL] [Abstract][Full Text] [Related]
8. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Schapira AH; Olanow CW Ann Neurol; 2003; 53 Suppl 3():S149-57; discussion S157-9. PubMed ID: 12666106 [No Abstract] [Full Text] [Related]
9. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. Löhle M; Reichmann H J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974 [TBL] [Abstract][Full Text] [Related]
10. Trial designs used to study neuroprotective therapy in Parkinson's disease. Lang AE; Melamed E; Poewe W; Rascol O Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060 [TBL] [Abstract][Full Text] [Related]
12. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. LeWitt PA J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399 [TBL] [Abstract][Full Text] [Related]
13. A responsive outcome for Parkinson's disease neuroprotection futility studies. Elm JJ; Goetz CG; Ravina B; Shannon K; Wooten GF; Tanner CM; Palesch YY; Huang P; Guimaraes P; Kamp C; Tilley BC; Kieburtz K; Ann Neurol; 2005 Feb; 57(2):197-203. PubMed ID: 15668964 [TBL] [Abstract][Full Text] [Related]
14. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. de la Fuente-Fernández R; Schulzer M; Mak E; Sossi V Parkinsonism Relat Disord; 2010 Jul; 16(6):365-9. PubMed ID: 20471298 [TBL] [Abstract][Full Text] [Related]
15. Imaging end points for monitoring neuroprotection in Parkinson's disease. Brooks DJ Ann Neurol; 2003; 53 Suppl 3():S110-8; discussion S118-9. PubMed ID: 12666103 [TBL] [Abstract][Full Text] [Related]
16. Management of Parkinson's disease a review of current and new therapies. Mendis T; Suchowersky O; Lang A; Gauthier S Can J Neurol Sci; 1999 May; 26(2):89-103. PubMed ID: 10352867 [TBL] [Abstract][Full Text] [Related]
17. The conundrum of neuroprotection in Parkinson's disease. Antonini A Lancet Neurol; 2011 May; 10(5):396-7. PubMed ID: 21482192 [No Abstract] [Full Text] [Related]
18. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Clarke CE Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348 [TBL] [Abstract][Full Text] [Related]
19. The vatican meeting on neuroprotection for Parkinson's disease. Olanow CW; Obeso JA; Stocchi F Mov Disord; 2013 Jan; 28(1):1-2. PubMed ID: 23390093 [No Abstract] [Full Text] [Related]
20. Preclinical development of gene therapy for Parkinson's disease. Porras G; Bezard E Exp Neurol; 2008 Jan; 209(1):72-81. PubMed ID: 17904121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]